FDA to Prioritize Biosimilars in Plan to Tackle Drug Prices

May 9, 2018

In the next few weeks, the Food and Drug Administration (FDA) will unveil a program to streamline approvals for complex drugs—commonly referred to as biosimilars—in an attempt to stem skyrocketing drug prices and improve drug accessibility for patients.

Related Stories